Conflict of Interest
Noonan, A. Sammons Cancer, Cancer
NOONAN, EMD, ANDERSEN, ONCOLOGY, CANCER
Jennifer K. Litton reports research support (to her institution) from AstraZeneca, EMD Serono, Genentech, GlaxoSmithKline, Medivation/Pfizer, Merck, Novartis, Pfizer, and Zenith Epigenetics; fees for participation on the ­speakers’ bureaus for Clinical Care Options, Med Learning Group, Medpage, Medscape, Physicians’ Education Resource, PrIME Oncology, and UpToDate; honoraria and patent/royalty payments from UpToDate; travel fees from Clinical Care Options, Med Learning Group, Medscape, and Physicians’ Education Resource; and consulting/advisory fees from AstraZeneca, Ayala Pharmaceuticals, Medivation/Pfizer, and Pfizer – all uncompensated. J. Thaddeus Beck reports research support (to his institution) from AbbVie, Amgen, Ascentage Pharma Group, AstraZeneca, Bayer, Boston Biomedical/Bristol Myers Squibb, Celgene, Daiichi Sankyo, EMD Serono, Evelo Biosciences, Genentech/Roche, GlaxoSmithKline, Hutchison, Immunomedics, Laekna Therapeutics, Lilly, Mirati Therapeutics, Nektar, Novartis, Pfizer, Polynoma, and Seattle Genetics. Jason M. Jones and Raymond Brig have nothing to disclose. Jay Andersen reports fees for participation on the speakers’ bureaus for AstraZeneca/Daiichi Sankyo, Genentech, Genomic Health, Immunomedics, Novartis, Puma Biotechnology, and Seattle Genetics; and consulting/advisory fees from AstraZeneca/Daiichi Sankyo, Athenex, Biotheranostics, Myriad, Novartis, Pfizer, Puma Biotechnology, and Seattle Genetics.Joanne L. Blum was a physician at Texas Oncology-Baylor Charles A. Sammons Cancer Center, US Oncology Network at the time these analyses were performed and reports consulting/advisory fees and honoraria from AstraZeneca, Athenex, Inc., Biotheranostics, Immunomedics, OncLive, Pfizer, Puma Biotechnology, Research to Practice, Sanofi, Tempus, and TD2 and participation on the speakers’ bureaus for Pfizer, and Tempus. Lida A. Mina was an employee at Banner MD Anderson Cancer Center at the time these analyses were performed and has nothing to disclose. Michael Danso reports consulting/advisory fees from Immunomedics, Novartis, Pfizer, and Seattle Genetics; and honoraria from Amgen. Yuan Yuan was an employee of the City of Hope Comprehensive Cancer Center and Beckman Research Institute at the time of these analyses and reports research support from Eisai, Genentech, and Merck; consulting/advisory fees from BCI Pharma, Daiichi Sankyo, Eisai, Genentech, Gilead, Novartis, Pfizer, and Puma Biotechnology; fees for participation on the speakers’ bureaus for AstraZeneca, Daiichi Sankyo/Lilly, Eisai, Genentech, Gilead, Merck, and Pfizer; and fees for expert testimony for Novartis. Antonello Abbattista, Alexander Niyazov, Jayeta Chakrabarti, and Akos Czibere are employees of Pfizer and hold stock. Kay Noonan was an employee at Pfizer at the time of this study. William F. Symmans reports consulting/advisory fees from Almac Diagnostics and Merck; support for travel from Luminex and Merck; stock ownership in Delphi Diagnostics, Eiger BioPharmaceuticals, ISIS Pharmaceuticals, and Nuvera Biosciences; and an uncompensated relationship with Delphi Diagnostics. Melinda L. Telli reports research support (to her institution) from AbbVie, Bayer, Biothera, Calithera Biosciences, EMD Serono, Genentech, Medivation, Merck, Novartis, OncoSec, Pfizer, PharmaMar, Tesaro, and Vertex; and consulting/advisory fees from AbbVie, Aduro Biotech, AstraZeneca, Celgene, Daiichi Sankyo, G1 Therapeutics, Genentech/Roche, Guardant, Immunomedics, Lilly, Merck, Natera, Novartis, OncoSec, Pfizer, and Sanofi.